Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle

Journal of Cardiovascular Pharmacology

Volumn 41, Issue 4, 2003, Pages 657-664

  Bonz, Andreas ^a   Laser, Martin ^a   Küllmer, Sina ^a   Kniesch, Silke ^a   Babin Ebell, Jörg ^a   Popp, Verena ^a   Ertl, Georg ^a   Wagner, Jens Andreas ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Anandamide; Atrium; Cannabinoid receptor; Contractile function; Human heart; Nitric oxide

Indexed keywords

6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DEXANABINOL; INDOMETACIN; METHANANDAMIDE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; CANNABINOID RECEPTOR; DRUG RECEPTOR;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; HEART ATRIUM CONTRACTILITY; HUMAN; HUMAN TISSUE; HYPOTENSION; IMMUNOFLUORESCENCE; INOTROPISM; ISOLATED HEART; PRIORITY JOURNAL; SYSTOLE; WESTERN BLOTTING; CHEMICAL PHENOMENA; DRUG POTENTIATION; HEART ATRIUM; HEART ATRIUM FUNCTION; HEART CONTRACTION; HEART MUSCLE; IN VITRO STUDY; METABOLISM; PHYSIOLOGY;

ATRIAL FUNCTION; CANNABINOIDS; DEPRESSION, CHEMICAL; HEART ATRIA; HUMANS; MYOCARDIAL CONTRACTION; MYOCARDIUM; RECEPTORS, CANNABINOID; RECEPTORS, DRUG;

EID: 0037379903     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200304000-00020     Document Type: Article

References (37)

1. Kunos G,Jarai Z, Varga K, et al. Cardiovascular effects of endocannabinoids: the plot thickens. Prostaglandins Lipid Med. 2000;61:71-84.
2. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561-4.
3. Ishac EJN,Jiang L, Lake KD, et al. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol. 1996;118:2023-8.
4. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61-5.
5. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946-9.
6. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995;50:83-90.
7. 1-like cannabinoid receptors. J Pharmacol Exp Ther. 1997;281:1030-7.
8. Niederhoffer N, Szabo B. Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. Br J Pharmacol. 1999;126:457-66.
9. Wagner JA, Varga K, Jarai Z, et al. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension. 1999;33:429-34.
10. 2+ channel current. Am J Physiol. 1999;266:H2085-93.
11. Wagner JA, Jarai Z, Batkai S, et al. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB1 receptors. Eur J Pharmacol. 2001;423:203-10.
12. Felder CC, Nielsen A, Briley EM, et al. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett. 1996;393:231-5.
13. Bilfinger TV, Salzet M, Fimiani C, et al. Pharmacological evidence for anandamide amidase in human cardiac and vascular tissues. Int J Cardiol. 1998;64:S15-22.
14. Bonz A, Vahl CF, Hagl S. Contractile behavior and intracellular calcium handling during afterloaded contractions in mitral valve disease. Thorac Cardiovasc Surg. 1997;45:280-6.
15. Bonz A, Herold U, Vahl CF, et al. Doxorubicin induced cardiomyopathy: comparison of physiological and morphologic analysis. Cor Europaeum. 1994;3:27-33.
16. Mulieri LA, Hasenfuss G, Ittleman F, et al. Protection of human left ventricular myocardium from cutting injury with 2,3-butanedione monoxime. CircRes. 1989;65:1441-9.
17. Vahl CF, Bonz A, Hagl C, et al. Reversible desensitization of the myocardial contractile apparatus for calcium: a new concept for improving tolerance to cold ischemia in human myocardium? Eur J Cardiothorac Surg. 1994;8:370-8.
18. Vahl CF, Bonz A, Hagl C, et al. "Cardioplegia on the contractile apparatus level": evaluation of a new concept for myocardial preservation in perfused pig hearts. Thorac Cardiovasc Surg. 1995;43:185-93.
19. Vahl CF, Bonz A, Timek T, et al. Intracellular calcium transient of working human myocardium of seven patients transplanted for congestive heart failure. Circ Res. 1994;74:952-8.
20. Laser M, Kasi VS, Hamawaki M, et al. Differential activation of p70 and p85 S6 kinase isoforms during cardiac hypertrophy in the adult mammal. J Biol Chem. 1998;273:24610-9.
21. Capasso JM, Li P, Guideri G, et al. Myocardial mechanical, biochemical, and structural alterations induced by chronic ethanol ingestion in rats. Circ Res. 1992;71:346-56.
22. 1 cannabinoid receptors in hemorrhagic shock. Nature. 1997;390: 518-21.
23. Wagner JA, Hu K, Bauersachs J, et al. Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J Am Coll Cardiol. 2001;38:2048-54.
24. Zygmunt PM, Petersson J, Andersson DA, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 1999;400:452-7.
25. Jarai Z, Wagner JA, Varga K, et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA. 1999;96:14136-41.
26. Grainger J, Boachie-Ansah G. Anandamide-induced relaxation of sheep coronary arteries: the role of the vascular endothelium, arachidonic acid metabolites and potassium channels. Br J Pharmacol. 2001; 134:1003-12.
27. White R, Ho W-SV, Bottrill FE, et al. Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries. Br J Pharmacol. 2001;134:921-9.
28. Ford WR, Honan SA, White R, et al. Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br J Pharmacol. 2002;135: 1191-8.
29. Galiègue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232:54-61.
30. Lagneux C, Lamontagne D. Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. Br J Pharmacol. 2001; 132:793-6.
31. 1 receptors. Eur J Pharmacol. 1996;307:331-8.
32. Ross RA, Brockie HC, Stevenson LA, et al. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of LY759633, LY759656, and AM-630. Br J Pharmacol. 1999;126: 665-72.
33. Deutsch DG, Chin SA. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol. 1993; 46:791-6.
34. Cotton JM, Kearney MT, MacCarthy PA, et al. Effects of nitric oxide synthase inhibition on basal function and the force-frequency relationship in the normal and failing human heart in vivo. Circulation. 2001;104:2318-23.
35. Amrani M, O'Shea J, Allen NJ, et al. Role of basal release of nitric oxide on coronary flow and mechanical performance of the isolated rat heart. J Physiol. 1992;456:681-7.
36. Lay L, Angus JA, Wright CE. Pharmacological characterisation of cannabinoid CB1 receptors in the rat and mouse. Eur J Pharmacol. 2000;391:151-61.
37. Molderings GJ, Likungu J, Göthert M. Presynaptic cannabinoid and imidazoline receptors in the human heart and their potential relationship. Naunyn Schmiedebergs Arch Pharmacol. 1999;360:157-64.